Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Christmas comes early for Agenus
The struggling US biotech receives a $150m windfall from Gilead, a group desperate to make its mark in oncology.
